Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast cancer adjuvant therapy.

P P Carbone1

  • 1University of Wisconsin Clinical Cancer Center Department of Human Oncology, University of Wisconsin Medical School, Madison 53792.

Cancer
|September 15, 1990
PubMed
Summary

Treatment for early breast cancer depends on stage, estrogen receptor (ER) status, and menopausal status. Chemotherapy and tamoxifen offer survival benefits for specific patient groups, guiding personalized treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryptococcus neoformans pericarditis associated with Hodgkin's disease.

Annals of internal medicine·2013
Same author

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

Annals of oncology : official journal of the European Society for Medical Oncology·2001
Same author

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2001
Same author

Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2000
Same author

Advances in the systemic treatment of cancers in the elderly.

Critical reviews in oncology/hematology·2000
Same author

PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma.

Investigational new drugs·1999

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • Combined modality trials for early breast cancer have been conducted since the 1960s.
  • Over 29,000 women have participated in 61 randomized trials.
  • Evidence guides treatment recommendations based on cancer stage and patient characteristics.

Purpose of the Study:

  • To summarize findings from extensive early breast cancer trials.
  • To provide stage, estrogen receptor (ER), and menopausal status-specific treatment recommendations.
  • To identify optimal therapies for diverse patient subsets.

Main Methods:

  • Analysis of data from 61 randomized trials involving over 29,000 women.
  • Stratification of results by cancer stage (I and II), ER status, and menopausal status.
  • Inclusion of data on chemotherapy and tamoxifen efficacy.

Main Results:

  • Chemotherapy impacts disease mortality in Stage II premenopausal women (ER-positive and ER-negative) and potentially in postmenopausal ER-negative patients.
  • Tamoxifen improves survival in postmenopausal Stage II ER-positive patients when used for over 2 years.
  • For node-negative patients, tamoxifen benefits ER-positive cases, while chemotherapy aids ER-negative cases, primarily improving disease-free survival.

Conclusions:

  • Treatment decisions for early breast cancer require careful consideration of stage, ER status, and menopausal status.
  • Chemotherapy and tamoxifen demonstrate specific benefits for distinct patient subgroups.
  • Future research will address optimal therapies for subsets with unmeasurable ER and incorporate novel prognostic markers like DNA synthesis and oncogene expression.

Related Experiment Videos